Skip to main content
. 2022 Jul 15;13:801337. doi: 10.3389/fphar.2022.801337

FIGURE 4.

FIGURE 4

Metformin suppresses the LPS-induced downregulation of SIRT1 both in vivo and in vitro. (A) Effects of metformin on the expression level of SIRT1 and NF-κB signaling pathway in pulmonary tissues of mice that received LPS intratracheally. Indicative bands are shown on the top of the histogram. Data are presented as mean ± SEM (n = 7). (B) Effects of metformin on the expression level of SIRT1 and NF-κB signaling pathway in primarily cultured pulmonary ECs. Representative bands are shown. Data are presented as mean ± SEM (n = 4). (C) Effects of metformin on the expression level of p65 lysine 310 acetylation in LPS-challenged mouse lung tissues. Data are presented as mean ± SEM (n = 7). (D) Effects of metformin on the expression level of p65 lysine 310 acetylation in LPS-treated pulmonary ECs. Data are presented as mean ± SEM (n = 4). **p < 0.01 vs. Control group, #p <0.05, ##p < 0.01 vs. LPS group.